Since the discovery of adipose-derived stem cells (ASCs), there have been high expectations of their putative clinical use. Recent advances support these expectations, and it is expected that the transition from pre-clinical and clinical studies to implementation as a standard treatment modality is imminent. However ASCs must be isolated and expanded according to good manufacturing practice guidelines and a basic assurance of quality, safety, and medical effectiveness is needed for authorisation by regulatory agencies, such as European Medicines Agency and US Food and Drug Administration. In this review, a collection of studies investigating the influence of different steps of the isolation and expansion protocol on the yield and functionality of ASCs has been presented in an attempt to come up with best recommendations that ensure potential beneficial clinical outcome of using ASCs in any therapeutic setting. If the findings confirm the initial observations of beneficial effects of ASCs, the path is paved for implementing these ASC-based therapies as standard treatment options.

中文翻译：

---

用于转化治疗的脂肪干细胞分离和扩增的关键步骤

自从发现脂肪源性干细胞 (ASCs) 以来，人们对其推定的临床应用抱有很高的期望。最近的进展支持了这些期望，并且预计从临床前和临床研究到实施作为标准治疗方式的转变迫在眉睫。然而，ASC 必须根据良好生产实践指南进行分离和扩展，并且需要对质量、安全性和医疗有效性进行基本保证，以便获得欧洲药品管理局和美国食品和药物管理局等监管机构的授权。在本次审查中，一系列研究调查了分离和扩增方案的不同步骤对 ASC 产量和功能的影响，试图提出最佳建议，以确保在任何治疗环境中使用 ASC 的潜在有益临床结果。如果研究结果证实了对 ASC 有益效果的初步观察，则为将这些基于 ASC 的疗法作为标准治疗方案实施铺平了道路。